Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821878 | 0.89 | EPHX1 (0.34) | TDP1ALDH1A1TSHRCA1CA7 | |
| SCHEMBL552810 | 0.89 | TSHR (0.33) | TDP1ALDH1A1TSHRCA1CA7 | |
| SCHEMBL26363425 | 0.87 | CRBN (0.36) | TDP1ALDH1A1TSHR | |
| SCHEMBL19821956 | 0.85 | CTSK (0.33) | TDP1ALDH1A1TSHRCA1CA7 | |
| SCHEMBL27500881 | 0.83 | TAS2R38 (0.40) | TDP1ALDH1A1TSHR | |
| SCHEMBL4887141 | 0.83 | EPHX1 (0.38) | TDP1ALDH1A1TSHRCA1CA7 | |
| SCHEMBL4887145 | 0.83 | EPHX1 (0.38) | TDP1ALDH1A1TSHRCA1CA7 | |
| SCHEMBL8404812 | 0.81 | EPHX1 (0.38) | TDP1ALDH1A1TSHRCA1CA12 | |
| SCHEMBL12499940 | 0.81 | LMNA (0.36) | TDP1ALDH1A1TSHRCA1CA7 | |
| SCHEMBL3342222 | 0.81 | TDP1 (0.46) | TDP1ALDH1A1TSHRCA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601798-B2 | Methods of preparing polymers having terminal amine groups using protected amine salts | ENZON PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-7569657-B2 | Methods of preparing polymers having terminal amine groups using protected amine salts | ENZON PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | claimed |
| EP-1931313-A2 | METHODS OF PREPARING POLYMERS HAVING TERMINAL AMINE GROUPS USING PROTECTED AMINE SALTS | Enzon Pharmaceuticals, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007044319-A2 | METHODS OF PREPARING POLYMERS HAVING TERMINAL AMINE GROUPS USING PROTECTED AMINE SALTS | ENZON PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-20070078257-A1 | Methods of preparing polymers having terminal amine groups using protected amine salts | BELROSE PHARMA INC. | 2007-04-05 | — | — | US | claimed |
| US-20070078219-A1 | METHODS OF PREPARING POLYMERS HAVING TERMINAL AMINE GROUPS USING PROTECTED AMINE SALTS | ENZON PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | claimed |
| US-20230203470-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | DADA2 FOUNDATION | 2023-06-29 | — | — | US | disclosed |
| US-11584923-B2 | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same | HALOZYME, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3207130-B1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | HALOZYME INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20180216095-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | DADA2 FOUNDATION | 2018-08-02 | — | — | US | disclosed |
| US-9969998-B2 | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same | HALOZYME, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-3207130-A2 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | Halozyme, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170166878-A9 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | DADA2 FOUNDATION | 2017-06-15 | — | — | US | disclosed |
| WO-2008034122-A2 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008034123-A2 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008034124-A2 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007146835-A2 | INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007044319-A2 | METHODS OF PREPARING POLYMERS HAVING TERMINAL AMINE GROUPS USING PROTECTED AMINE SALTS | ENZON PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070078257-A1 | Methods of preparing polymers having terminal amine groups using protected amine salts | BELROSE PHARMA INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070078219-A1 | METHODS OF PREPARING POLYMERS HAVING TERMINAL AMINE GROUPS USING PROTECTED AMINE SALTS | ENZON PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166878-A9 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | ADA, CDA, ADAR | TDP1 139/4885ALDH1A1 339/4885TSHR 3239/4885 |
| US-20180216095-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | ADA, CDA, ADAR | TDP1 139/4885ALDH1A1 339/4885TSHR 3239/4885 |
| US-11584923-B2 | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same | ADA, CDA, ADAR | TDP1 139/4885ALDH1A1 339/4885TSHR 3239/4885 |
| US-20230203470-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | ADA, CDA, ADAR | TDP1 139/4885ALDH1A1 339/4885TSHR 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.